Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amarin Shuffles Management Again, But Says Omega-3 Trial Results Are Near

This article was originally published in The Pink Sheet Daily

Executive Summary

On a quarterly earnings call, Amarin's new CEO says two Phase III trials of a drug to lower triglycerides will yield results a few months ahead of schedule.

You may also be interested in...



Amarin Raises $100M Debt Funding As It Preps For Vascepa Launch

With no partner or buyer ready to complete a transaction, Amarin prepares to market an approved fish-oil pill on its own. A new hybrid debt vehicle will tide it over until it receives more clarity around an NCE designation and a second indication, which it hopes could eventually lead to a deal.

Amarin Raises $100M Debt Funding As It Preps For Vascepa Launch

With no partner or buyer ready to complete a transaction, Amarin prepares to market an approved fish-oil pill on its own. A new hybrid debt vehicle will tide it over until it receives more clarity around an NCE designation and a second indication, which it hopes could eventually lead to a deal.

Swimming Solo For Now, Amarin Faces Challenges Commercializing Vascepa

Despite a labeling advantage when it comes to LDL, Amarin’s newly approved Vascepa faces a daunting commercial landscape, competing against Glaxo’s entrenched, soon-to-be generic Lovaza and other options for lowering triglycerides.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071421

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel